Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.52 |
| ▸ | HTR1D | P28221 | 10/20 | 0.48 |
| ▸ | HTR1B | P28222 | 9/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078452 | 0.80 | HTR1D (0.68) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078331 | 0.79 | ADRA1A (0.50) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078348 | 0.79 | ADRA1A (0.51) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078518 | 0.78 | HTR1D (0.47) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078507 | 0.77 | HTR1D (0.57) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078533 | 0.76 | ADRA2C (0.44) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078333 | 0.75 | ADRA1A (0.51) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078491 | 0.75 | TAAR1 (0.51) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078349 | 0.75 | ADRA1A (0.48) | ADRA1DADRA1AADRA1BHTR1DHTR1B | |
| SCHEMBL26078482 | 0.73 | TAAR1 (0.56) | ADRA1DADRA1AADRA1BHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | ADRA1D 3/4885ADRA1A 1/4885ADRA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.